Advertisement

Topics

Latest "Gritstone Oncology" News Stories

03:04 EDT 14th August 2018 | BioPortfolio

Here are the most relevant search results for "Gritstone Oncology" found in our extensive news archives from over 250 global news sources.

More Information about Gritstone Oncology on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Gritstone Oncology for you to read. Along with our medical data and news we also list Gritstone Oncology Clinical Trials, which are updated daily. BioPortfolio also has a large database of Gritstone Oncology Companies for you to search.

Showing "Gritstone Oncology" News Articles 1–25 of 4,100+

Extremely Relevant

Gritstone Oncology Receives Notice of Allowance from U.S. ...

Gritstone to be Issued Patent for its EDGE™ Deep Learning Model to Identify Neoantigens for Inclusion in Personalized Cancer Immunotherapies Read more...


Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration

NewsBristol-Myers Squibb and Gritstone Oncology have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy in combination with Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab), and Opdivo plus Yervoy (ipilimumab), in patients with advanced solid tumors.

Bristol-Myers Squibb and Gritstone Oncology Partner to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors

EMERYVILLE, Calif. & NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001, which comprises sequential delivery of neoantigens to patients within an adeno...


Bristol-Myers Squibb and Gritstone to start Phase l trial for tumours

Bristol-Myers Squibb Company has entered a clinical trial collaboration with Gritstone Oncology to examine the safety and tolerability of GRANITE-001...Read More... The post Bristol-Myers Squibb and Gritstone to start Phase l trial for tumours appeared first on Drug Development Technology.

Relevant

Gritstone Oncology to Present at Cowen and Company 38th Annual Health Care Conference

Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced that Andrew Allen, M.D., PhD., President and Chief Executive Officer, will present at Cowen and Company’s 38th Annual Health Care Conference. The presentation will take place on Monday, March 12, 2018 at 8:30 a.m. Eastern Time at the Boston Marriott ...

Gritstone Oncology Appoints Experienced Financial Executive, Steve E. Krognes, to its Board of Directors

Gritstone Oncology, Inc., an immuno-oncology company developing tumor-specific cancer immunotherapies to fight multiple cancer types, today announced the appointment of Steve E. Krognes to the company’s board of directors. Mr. Krognes, who currently serves as the chief financial officer of Denali Therapeutics Inc., brings more than 25 years of finance an...

Gritstone Oncology Receives Notice of Allowance from U.S. Patent and Trademark Office on its Core Patent Application for Tumor Antigen Prediction Model

Gritstone to be Issued Patent for its EDGE™ Deep Learning Model to Identify Neoantigens for Inclusion in Personalized Cancer Immunotherapies Gritstone Oncology, Inc., an immuno-oncology company developing personalized cancer immunotherapies to fight multiple cancer types, announced today that that it has received a Notice of Allowance from the United...

Gritstone Oncology Appoints Jayant Aphale, Ph.D. as Executive Vice President of Technical Operations

Senior Biopharma Executive Brings More Than 25 Years of Global Pharmaceutical Production and Supply Experience Across Vaccines, Biologics and Oligonucleotides Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced that Jayant Aphale, Ph.D. has been appointed as Executive Vice President of Technical Op...

Gritstone Oncology Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12032018] Prices from USD $250

SummaryGritstone Oncology Inc Gritstone is a cancer immunotherapy company which focuses on the development of personalized cancer therapeutics. The company primarily concentrates on identifying and deploying the therapeutic neoantigens from individual patients' tumors for the development of novel treatments for lung cancer. Gritstone works in collaboration with other organizations such as Immune D...

Gritstone Oncology to Present First Data Bridging Tumor Antigen Identification and Potent Immunotherapy Delivery in Primates at 2018 AACR Annual Meeting

Data Support Plans to Initiate Clinical Trials in 2H18 Gritstone Oncology, a personalized cancer immunotherapy company, today announced that preclinical data highlighting the company’s tumor-specific neoantigen (TSNA) identification platform, EDGETM (Epitope Discovery in cancer GEnomes), and a novel, potent TSNA delivery approach will be presented du...

Ockham Oncology’s CSO highlights global strength of fully integrated company.

Ockham Oncology’s Chief Scientific Officer Clare Wareing, PhD recounts the companies history and emphasizes complementary strengths that add value following the combination of Ockham Oncology and Nexus Oncology.

Analysis of oncology pipeline

Oncology research, which includes the medical, radiation, and surgical fields, is always ongoing. Therefore, the oncology pipeline is a key...Read More... The post Analysis of oncology pipeline appeared first on Pharmaceutical Technology.

Next Steps for Immunotherapies, Cell Therapies in Oncology

At ESMO 2017, Drs Zimmermann, Svane, and Coukos discuss successes and setbacks in immuno-oncology. Medscape Oncology

Axel Hoos, GSK: Focusing on immuno-oncology and cancer epigenetics

GSK has had a recent change in Oncology after recently divesting their marketed oncology products to Novartis whilst retaining their R&D pipeline. During BIO 2015, Axel Hoos, VP Oncology R&D at GSK explained to Fintan Walton, CEO of PharmaVentures what these changes will mean and how they are now focussing on two areas of cutting edge science.

Representation of Minorities and Women in Oncology Trials

Do clinical trials in oncology adequately represent the US population with cancer? Journal of Oncology Practice

ASCO endorses the integration of quackery into breast cancer care

In 2014, the Society for Integrative Oncology first published clinical guidelines for the care of breast cancer patients. Not surprisingly, SIO advocated "integrating" dubious therapies with oncology. Last week, the most influential oncology society, the American Society of Clinical Oncology (ASCO), endorsed a 2017 update to the SIO guidelines, thus endorsing the "integration" of quackery with onc...

'Tremendous Loss' of a Giant in Psycho-Oncology

Dr Mark Kris pays tribute to a true giant in the field of oncology and his dear friend, Jimmie Holland. Medscape Oncology

'Moving the Needle' in Oncology Workforce Diversity

Authors of a recent ASCO statement on diversity discuss their experiences and suggestions for improving inclusivity in the oncology workforce. Medscape Oncology

Immuno-Oncology Conference 2018

26 - 27 September, London, UK. Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.

Shire announces sale of oncology business to Servier for $2.4 billion

Oncology business provides Servier with an immediate presence in the US, enhancing its commitment to addressing unmet patient needs in oncology

Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development

Dr. Gandhi is currently the Director of Thoracic Medical Oncology and an associate professor of medicine at the New York University( NYU) School Read more...

Asembia expands collaboration with Pfizer oncology

Asembia has announced that it members can now gain expanded access to Pfizer oncology defined distribution oncology products for qualified hospital and health system clients.

License Agreement: Clovis Oncology $CLVS (Ethical Oncology Science, S.p.A, Servier, SA, and Advenchen Laboratories, LLC)

November 2013, Clovis Oncology ($CLVS @ClovisOncology) acquired Ethical Oncology Science, S.p.A. (“EOS”) (known as Clovis Oncology Italy S.r.l., or “COI”) through which the rights to lucitanib were obtained. 2008, EOS had in-licensed exclusive development and commercial rights to lucitanib on a global basis, excluding China, from Advenchen Laboratories. September 2012, EOS entered into a...

10 Top Immuno-Oncology Companies

One of the most highly anticipated methods to fight cancer is the immuno-oncology (I/O) sector. For investors interested in the field the Investing News Network (INN) has put together a list of top immuno-oncology companies. The post 10 Top Immuno-Oncology Companies appeared first on Investing News Network.

Oncology Nursing News® Hosts Tweet Chat on Oncology Nursing Society's Annual Conference

Oncology Nursing News® will be hosting its first tweet chat on May 23, at 1 p.m. ET, to discuss findings presented at the Oncology Nursing Society's (ONS) Annual Conference, held May 17-20 in Washington, D.C. “We are excited to launch the inaugural tweet chat on the oncology nursing society’s annual conference. This tweet chat will inform the...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks